立体定向体部放疗治疗I期非小细胞肺癌患者的真实世界急性毒性与90天死亡率
基于荷兰肺癌放疗审计(DLCA-R)2017至2021年前瞻性全国数据,纳入7279例接受立体定向体部放疗(SBRT)的I期非小细胞肺癌(NSCLC)患者,急性毒性发生280例(3.8%),90天死亡122例(1.7%);高龄未增加急性毒性或死亡风险,所建预测模型性能满意。
要点
- 7279例接受SBRT的I期NSCLC患者中,急性毒性280例(3.8%),90天死亡122例(1.7%)。
- 急性毒性预测因素包括WHO评分≥2、FEV1与DLCO较低、无病理确诊、中下叶肿瘤、cT1c-cT2a期及较高平均肺剂量(c统计量0.68)。
- 男性、WHO评分≥2及急性毒性预测更高的90天死亡率(c统计量0.73)。
核心结论
- 这项全国性研究显示,接受SBRT治疗的I期NSCLC患者急性毒性发生率低、90天死亡率可接受;高龄未增加急性毒性或死亡风险;预测模型性能满意,为识别高危患者提供工具。
研究设计与样本
- 前瞻性收集荷兰肺癌放疗审计(DLCA-R)全国数据,纳入2017至2021年接受SBRT的I期NSCLC(cT1-2aN0M0)患者,共7279例,并开发及内部验证急性毒性与90天死亡率的预测模型。
主要发现
- 患者平均年龄72.5岁,80岁以上占21.6%,男性占50.7%,WHO评分0至1占73.3%,cT1a-b肿瘤占64.6%,上叶肿瘤占65.2%。
- 急性毒性(定义为SBRT后90天内≥2级放射性肺炎或≥3级非血液学毒性)发生280例(3.8%),90天死亡122例(1.7%)。
- 急性毒性预测因素包括WHO评分≥2、FEV1与DLCO较低、无病理确诊、中下叶肿瘤位置、cT1c-cT2a期及较高平均肺剂量(c统计量0.68)。
- 男性、WHO评分≥2及急性毒性预测更高的90天死亡率(c统计量0.73)。
关键数值与推荐
- 急性毒性定义为SBRT后90天内≥2级放射性肺炎或≥3级非血液学毒性。
- 急性毒性预测模型c统计量0.68,90天死亡率预测模型c统计量0.73。
临床怎么用
- 作者认为,所建预测模型性能满意,可作为识别高危患者的工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Stereotactic body radiotherapy (SBRT) has firmly established its role in stage I NSCLC. Clinical trial results may not fully apply to real-world scenarios. This study aimed to uncover the real-world incidence of acute toxicity and 90-day mortality in patients with SBRT-treated stage I NSCLC and develop prediction models for these outcomes. METHODS: Prospective data from the Dutch Lung Cancer Audit for Radiotherapy (DLCA-R) were collected nationally. Patients with stage I NSCLC (cT1-2aN0M0) treated with SBRT in 2017 to 2021 were included. Acute toxicity was assessed, defined as grade greater than or equal to 2 radiation pneumonitis or grade greater than or equal to 3 non-hematologic toxicity less than or equal to 90 days after SBRT. Prediction models for acute toxicity and 90-day mortality were developed and internally validated. RESULTS: Among 7279 patients, the mean age was 72.5 years, with 21.6% being above 80 years. Most were male (50.7%), had WHO scores 0 to 1 (73.3%), and had cT1a-b tumors (64.6%), predominantly in the upper lobes (65.2%). Acute toxicity was observed in 280 (3.8%) of patients and 90-day mortality in 122 (1.7%). Predictors for acute toxicity included WHO greater than or equal to 2, lower forced expiratory volume in 1 second and diffusion capacity for carbon monoxide, no pathology confirmation, middle or lower lobe tumor location, cT1c-cT2a stage, and higher mean lung dose (c-statistic 0.68). Male sex, WHO greater than or equal to 2, and acute toxicity predicted higher 90-day mortality (c-statistic 0.73). CONCLUSIONS: This nationwide study revealed a low rate of acute toxicity and an acceptable 90-day mortality rate in patients with SBRT-treated stage I NSCLC. Notably, advanced age did not increase acute toxicity or mortality risk. Our predictive models, with satisfactory performance, offer valuable tools for identifying high-risk patients.
引用
- van Rossum PSN, Wolfhagen N, van Bockel LW, et al. Real-World Acute Toxicity and 90-Day Mortality in Patients With Stage I NSCLC Treated With Stereotactic Body Radiotherapy. J Thorac Oncol. 2024. PMID: 39067700. doi:10.1016/j.jtho.2024.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。